Premium
P1‐015: Brain and hippocampal rates of atrophy in familial Alzheimer's disease mutation carriers: Preliminary findings from the DIAN study
Author(s) -
Kinnunen Kirsi,
Cash David,
Leung Kelvin,
Liang Yuying,
Cardoso Manuel,
Modat Marc,
Malone Ian,
Benzinger Tammie,
Koeppe Robert,
Jack Clifford,
Raichle Marc,
Marcus Daniel,
Ringman John,
Thompson Paul,
Saykin Andrew,
Ghetti Bernardino,
Salloway Stephen,
Correia Stephen,
Johnson Keith,
Sperling Reisa,
Schofield Peter,
Rowe Christopher,
Masters Colin,
Villemagne Victor,
Brickman Adam,
Mayeux Richard,
Martins Ralph,
Weiner Michael,
Bateman Randall,
Goate Alison,
Buckles Virginia,
Moulder Krista,
Morris John,
Rossor Martin,
Ourselin Sebastien,
Fox Nick
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.290
Subject(s) - atrophy , clinical dementia rating , medicine , asymptomatic , dementia , hippocampal formation , cohort , alzheimer's disease , cardiology , pathology , disease
However, AD patients in advanced clinical stage, as determined by low MMSE score ( 20), had lower BACE1 activity and sAPP 6 , sAPPb and Ab40 concentrations than patients with higher MMSE score. Conclusions: Our results highlight the strong diagnostic power of the core CSF biomarkers for AD. We also suggest that BACE1 activity and sAPP6 , sAPPb and Ab40 concentrations may be related to the severity of the disease.